west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "郭海鹰" 3 results
  • 骨髓增殖性肿瘤发病机制的研究进展及临床应用

    【摘要】 近年来大量的研究对骨髓增殖性疾病发病机制有了更进一步的认识。其中最重要的发现是出现在绝大多数阵型红细胞增多症和一半左右原发性血小板增多症及骨髓纤维化的JAK2 V617F突变,能使细胞增殖活性明显增强,并引起细胞的增殖和凋亡抑制。其他的突变包括JAK2外显子12突变、MPL突变等。对慢性粒细胞白血病的急变机制及对伊马替尼的耐药机制也有了更多的认识。这些新的发现影响了慢性骨髓增殖性肿瘤的诊断标准与流程,并对其治疗提供了新的靶点。

    Release date:2016-08-26 02:18 Export PDF Favorites Scan
  • 外周血粒细胞缺乏症感染实验室诊断的进展

    【摘要】 恶性血液病患者强烈化疗诱导的粒细胞缺乏症常并发感染,且病死率高。快速而准确地进行病原学诊断,尽早使用抗生素为治疗争取时间,可大大降低感染病死率。而临床常用感染的实验室诊断指标均有其局限性, 不能满足临床需要。目前国内外多项研究提示降钙素原、白介素-6、内毒素有助于粒细胞缺乏症伴感染的诊断及治疗。现就降钙素原、白介素-6、内毒素的来源、生物学活性及在临床中的应用做一综述。

    Release date:2016-08-26 02:18 Export PDF Favorites Scan
  • Clinical and Laboratory Study of a Case of Chronic Myelogenous Leukemia Blastic Transformation with Rare Hypodiploid t(1;9;22)

    【摘要】 目的 观察慢性粒细胞性白血病(chronic myelogenous leukemia, CML)急变(blast crisis,BC)患者罕见染色体异常的临床及实验室特点。 方法 2010年2月1例患者因咳嗽和高热来我院就诊,采用常规方法检查患者骨髓细胞,应用R显带技术和荧光原位杂交技术分析骨髓细胞核型。 结果 患者具有CML-BC的典型临床及实验室特点,同时核型出现不典型t(1;9;22)合并亚二倍体罕见核型异常,临床表现病情进展快,对伊马替尼疗效差,生存期短。 结论 慢性粒细胞性白血病患者在急变期出现伴不典型Ph染色体的亚二倍体复杂核型为高危核型,此类患者可能存在对伊马替尼的耐药,如能取得血液学缓解应尽早接受异基因骨髓造血干细胞移植,争取获得长期疗效。【Abstract】 Objective To report a case of chronic myelogenous leukemia (CML) blastic transformation into acute myelogenous leukemia with rare atypical hypodiploid t(1;9;22) complex chromosome abnormalities, and to analyze its clinical and laboratory characteristics.  Methods A 47-year-old man was referred to our hospital due to cough and high fever in February 2010. We collected and analyzed the patient’s clinical materials, and performed chromosomal karyotype analysis with R-banding and fluorescence in situ hybridization (FISH). Results The patient demonstrated typical clinical and laboratory characteristics of blastic crisis of chronic myelogenous leukemia (CML-BC) and displayed rare atypical hypodiploid t(1;9;22) complex chromosome abnormalities. Meanwhile, the disease was rapidly progressive, with poor response to imatinib and had short overall survival. Conclusions CML-BC patients with hypodiploidy complex chromosome abnormalities are in high risk. They may show drug-resistance to imatinib. Thus, for this type of patients, once the hematological remission is achieved, allogeneic stem cell transplant should be performed as soon as possible to get better opportunity for long-term survival.

    Release date:2016-09-08 09:26 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content